Total Synthesis of (±)-Quinagolide: A Potent D2 Receptor Agonist for the Treatment of Hyperprolactinemia

Documenti analoghi

• Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors
  di: Galina Afanas'evna Melnichenko, et al.
  Pubblicazione: (2015-04-01)
• Long-term follow-up of medically treated prolactinomas in men: effect on tumor size, hyperprolactinemia, and erectile dysfunction
  di: Mohamed Farouk Elsherif, et al.
  Pubblicazione: (2025-12-01)
• The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
  di: Zilya A. Kalmykova, et al.
  Pubblicazione: (2019-09-01)
• Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
  di: Youngki Lee, et al.
  Pubblicazione: (2014-09-01)
• A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas
  di: Rakesh Mishra, et al.
  Pubblicazione: (2021-01-01)